Compare FDP & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FDP | TYRA |
|---|---|---|
| Founded | 1886 | 2018 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 1999 | 2021 |
| Metric | FDP | TYRA |
|---|---|---|
| Price | $41.83 | $35.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $46.78 |
| AVG Volume (30 Days) | 264.5K | ★ 931.2K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.88 | N/A |
| Revenue | ★ $4,322,300,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.14 | N/A |
| P/E Ratio | $22.75 | ★ N/A |
| Revenue Growth | ★ 0.98 | N/A |
| 52 Week Low | $30.92 | $7.80 |
| 52 Week High | $43.58 | $40.65 |
| Indicator | FDP | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 52.44 | 46.37 |
| Support Level | $39.86 | $34.01 |
| Resistance Level | $43.30 | $39.90 |
| Average True Range (ATR) | 1.32 | 2.46 |
| MACD | 0.06 | -0.39 |
| Stochastic Oscillator | 65.10 | 19.28 |
Fresh Del Monte Produce Inc is an integrated producer, marketer & distributor of fresh-cut fruit & vegetables. It operates in three segments, Fresh and value-added products segment, which includes pineapples, fresh-cut fruit, fresh-cut vegetables, melons, vegetables, non-tropical fruit, other fruit and vegetables, avocados, and prepared foods, Banana segment & Other products and services segment, including the third-party freight & logistic services business & the Jordanian poultry and meats business. The majority is from the Fresh and value-added products segment. Geographically, it operates in North America, Europe, Asia, the Middle East, and Other, out of which the highest is from North America.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.